Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP

Biochemical and Biophysical Research Communications

Volumn 432, Issue 2, 2013, Pages 320-325

  Zhao, Hu ^a   Zhu, Chen ^a   Qin, Chao ^a   Tao, Tao ^a   Li, Jie ^a   Cheng, Gong ^a   Li, Pu ^a   Cao, Qiang ^a   Meng, Xiaoxin ^a   Ju, Xiaobing ^a   Shao, Pengfei ^a   Hua, Lixin ^a   Gu, Min ^a   Yin, Changjun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Androgen receptor; Fenofibrate; LNCaP; Oxidative stress

Indexed keywords

ANDROGEN RECEPTOR; FENOFIBRATE; MALONALDEHYDE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; FENOFIBRATE; HUMANS; MALE; OXIDATIVE STRESS; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SERINE ENDOPEPTIDASES; TRANSCRIPTION, GENETIC;

EID: 84875232583     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.105     Document Type: Article

References (22)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2009, 59:225-249.
2. Garnick M.B. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology 1997, 49:5-15.
3. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
4. Burnstein K.L. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J. Cell. Biochem. 2005, 95:657-669.
5. Kaarbo M., Klokk T.I., Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 2007, 29:1227-1238.
6. Dehm S.M., Tindall D.J. Regulation of androgen receptor signaling in prostate cancer. Expert Rev. Anticancer Ther. 2005, 5:63-74.
7. van der Hoogt C.C., de Haan W., Westerterp M., Hoekstra M., Dallinga-Thie G.M., Romijn J.A., Princen H.M., Jukema J.W., Havekes L.M., Rensen P.C. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J. Lipid Res. 2007, 48:1763-1771.
8. Drukala J., Urbanska K., Wilk A., Grabacka M., Wybieralska E., Del Valle L., Madeja Z., Reiss K. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro. Mol. Cancer 2010, 9:159.
9. Deleon M.J., Horani M.H., Haas M.J., Wong N.C., Mooradian A.D. Effects of dehydroepiandrosterone on rat apolipoprotein AI gene expression in the human hepatoma cell line, HepG2. Metabolism 2002, 51:376-379.
10. Saidi S.A., Holland C.M., Charnock-Jones D.S., Smith S.K. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol. Cancer 2006, 5:13.
11. Tsui K.H., Feng T.H., Lin C.M., Chang P.L., Juang H.H. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J. Androl. 2008, 29:661-668.
12. Reddy G.P., Barrack E.R., Dou Q.P., Menon M., Pelley R., Sarkar F.H., Sheng S. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J. Cell. Biochem. 2006, 98:1408-1423.
13. Cornu-Chagnon M.C., Dupont H., Edgar A. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam. Appl. Toxicol. 1995, 26:63-74.
14. Yamasaki D., Kawabe N., Nakamura H., Tachibana K., Ishimoto K., Tanaka T., Aburatani H., Sakai J., Hamakubo T., Kodama T., Doi T. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARalpha-independent mechanisms. Eur. J. Cell Biol. 2011, 90:657-664.
15. Asavapanumas N., Kittayaruksakul S., Meetam P., Muanprasat C., Chatsudthipong V., Soodvilai S. Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARalpha-independent pathways. Drug Metab. Pharmacokinet. 2012, 27:513-519.
16. Baliga B.C., Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol. Oncol. 2002, 20:63-74.
17. Kandel E.S., Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253:210-229.
18. Goetze S., Eilers F., Bungenstock A., Kintscher U., Stawowy P., Blaschke F., Graf K., Law R.E., Fleck E., Grafe M. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem. Biophys. Res. Commun. 2002, 293:1431-1437.
19. Varet J., Vincent L., Mirshahi P., Pille J.V., Legrand E., Opolon P., Mishal Z., Soria J., Li H., Soria C. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell. Mol. Life Sci. 2003, 60:810-819.
20. Chen K., Li Y.H., Xu S.Q., Hu S.H., Zhang L. Protective Effects of Peroxisome Proliferator-Activated Receptor-alpha Agonist, Wy14643, on Hypoxia/Reoxygenation Injury in Primary Rat Hepatocytes. PPAR Res. 2012, 2012:547980.
21. Ropero A.B., Juan-Pico P., Rafacho A., Fuentes E., Bermudez-Silva F.J., Roche E., Quesada I., de Fonseca F.R., Nadal A. Rapid non-genomic regulation of Ca2+ signals and insulin secretion by PPAR alpha ligands in mouse pancreatic islets of Langerhans. J. Endocrinol. 2009, 200:127-138.
22. Gamaley I.A., Klyubin I.V. Roles of reactive oxygen species: signaling and regulation of cellular functions. Int. Rev. Cytol. 1999, 188:203-255.